Per Reuters' reporting, this morning -- HGSI's next generation of Hep C treatments, ones that will compete with legacy Schering-Plough's PegIntron® product -- have shown promise in mid-stage trials:
. . . .Human Genome Sciences Inc said interim data from a mid-stage study testing a monthly-dosing version of its experimental hepatitis C treatment, Zalbin®, showed the drug's efficacy was comparable with the current standard of care.
Human Genome and its partner Novartis AG have already submitted an application to the U.S. health regulators for a version of Zalbin dosed every two weeks and received a review date of October 4, 2010. . . .
The two current leading interferons, Pegasys and Merck's Pegintron are taken intravenously [sic; Ed. Note (per comment below) -- in fact, these medicines are self-injected, not "dripped" by IV bag] once a week for up to 48 weeks in combination with the antiviral pill ribavirin, while Zalbin is injected [only once] every two weeks.
Human Genome shares were up 1 percent to $32.55 in premerket trade. They had closed at $32.10 Tuesday on NASDAQ. . . .